Plain-English translation of NCT05893381 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Prostate Cancer research guide โPhase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach for men with prostate cancer that has come back or spread to only a few locations in the body. Participants will receive a type of targeted radiation therapy that focuses high doses on cancer spots. Half will receive this radiation alone, and half will also receive Lutetium-177 PSMA, a radioactive medication that targets cancer cells. Researchers want to see if adding this medication helps prevent the cancer from growing further.
When prostate cancer comes back after initial treatment, it often spreads to only one to three spots in the body before spreading more widely. Current radiation therapy works well for controlling these early spread sites, but doctors want to know if adding a targeted radioactive treatment can do even better and give patients longer-lasting protection.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join this trial, you will be randomly assigned to receive either targeted radiation therapy alone or the same radiation therapy plus two cycles of the radioactive medication given about 6โ8 weeks apart. You will have imaging scans and blood tests to monitor how well the treatment is working and to check for side effects. The radiation is delivered in 1 to 5 treatment sessions, and your participation will span several months as the medication cycles are completed and you are followed for safety and effectiveness.
AI-generated summary from trial data ยท Jun 3, 2026 ยท Not medical advice
Italy